allogene.com - ALLO Enterprise Value-to-Sales Ratio

Public company logo of Allogene Therapeutics, Inc. (ALLO)

Allogene Therapeutics (ALLO) is expanding its oncology presence by scaling universal CAR-T systems while strictly adhering to environmental chemical disposal regulations. This EV/Sales chart visualizes the impact of these factors on market value, where 3241.38 determines the current metric value. High pent-up demand from hospitals for affordable cell therapy is expected to support further growth in the company's share price.

allogene.com (ALLO): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

Financial and market metric breakdowns for Allogene Therapeutics Inc (ALLO)

Fundamental valuation:Allogene Therapeutics (ALLO)
Core merchandise of Allogene Therapeutics, Inc.

Investors seek an equilibrium between asset valuation and business quality. This metric correlates the total enterprise value, adjusted for net debt, with the volume of generated sales. For Allogene Therapeutics (ALLO), this calculation reflects the market valuation of the potential for licensing royalties and patents within the cell therapy sector. The analysis reveals how aggressively the market prices in the future monetization of these technologies. This trend is captured by the historical EV/Sales level.